Skip to content
Screener

Ocular Therapeutix OCUL Business Segments — D&A

Similar metrics at other companies

Dollar General logo
DGSingle Reportable — D&A
$260M+7.0%
Citi Trends logo
CTRNSingle Reportable — D&A
$5.11M+16.9%
Monarch Casino & Resort logo
MCRISingle Reportable — D&A
$10.66M-21.4%
Payoneer Global Inc. logo
PAYOSingle Reportable — D&A
$21.22M+36.5%
Clean Energy Fuels logo
CLNESingle Reportable — D&A
$10.68M+7.2%
El Pollo Loco logo
LOCOSingle Reportable — D&A
$4.17M+6.0%

Other financials

Income statement

See full
Revenue$10.8M+0.8%
Gross profit$9.5M+0.2%
Operating income-$93.3M-46.0%
Net income-$88.6M-38.3%
EPS (diluted)-$0.40-5.3%

Balance sheet

See full
Cash & equivalents$666.7M+90.7%
Total debt$79.5M+4.2%
Total equity$581.6M+119%
Total assets$732.5M+80.5%

Cash flow

See full
Operating cash flow-$66.0M-47.7%
CapEx$4.7M+141%
Free cash flow-$70.7M-51.6%

Valuation

See full
Market cap$1.92B-11.7%
Enterprise value$1.33B-28.4%
P/S36.9×-1.5×

Profitability

See full
Gross margin87.2%-3.4pp
Operating margin-575.4%+1,233pp
Net margin-558.2%+1,493pp
FCF margin-463%+2,860pp

Returns & leverage

See full
Return on equity-68.6%+17.0pp
Debt / equity0.1×-0.2×
Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: Ocular Therapeutix’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 7:28 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-055256
Line itemThree Months Ended / March 31, 2026Three Months Ended / March 31, 2025
General and administrative (a)11,6069,661
Facilities (b)2,2701,664
Stock-based compensation15,58210,456
Depreciation1,260981
Interest income6,0503,826
Interest expense(2,777)(2,984)
Other non-operating items1,455(978)
Net loss$(88,612)$(64,053)

Item 1. Financial Statements (unaudited)

FAQ

What is Ocular Therapeutix's business segments — D&A?
Ocular Therapeutix (OCUL) reported business segments — D&A of $1.26M in Q1 2026.
How has Ocular Therapeutix's business segments — D&A changed year-over-year?
Ocular Therapeutix's business segments — D&A increased by 28.4% year-over-year, from $981K to $1.26M.
What is the long-term trend for Ocular Therapeutix's business segments — D&A?
Over 3 years (2022 to 2025), Ocular Therapeutix's business segments — D&A has grown at a 27.1% compound annual growth rate (CAGR), from -$2.11M to $4.33M.
What does business segments — D&A mean?
This metric represents the non-cash allocation of the cost of tangible and intangible assets over their useful lives within the company's primary business segment. It reflects the consumption of capital investments required to support the development and manufacturing of ophthalmic therapeutic products. Monitoring this helps investors understand the capital intensity of the company's operations.

Ask your AI about Ocular Therapeutix's business segments — d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude